0001104659-22-047062.txt : 20220419 0001104659-22-047062.hdr.sgml : 20220419 20220419070049 ACCESSION NUMBER: 0001104659-22-047062 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220419 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220419 DATE AS OF CHANGE: 20220419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 22833445 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 8-K 1 tm2212889d1_8k.htm FORM 8-K
0000827871 false 0000827871 2022-04-19 2022-04-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 19, 2022

 

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36306 20-8179278
(State or other jurisdiction of (Commission File Number)   (IRS Employer Identification No.)  
incorporation)    

 

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ		   07677
(Address of principal executive offices)     (Zip Code)  

 

Registrant’s telephone number, including area code: (201) 326-5300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock (par value $0.001 per share)   EGRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01           Other Events.

 

On April 19, 2022, or the Effective Date, Eagle Pharmaceuticals, Inc., or the Company, entered into a definitive settlement agreement, or the Settlement Agreement, with Hospira, Inc., or Hospira, relating to the Company’s product BENDEKA® (rapidly infused bendamustine hydrochloride). This settlement resolves patent litigation brought by the Company and its marketing partners Teva Pharmaceuticals International, GmbH and Cephalon, Inc. relating to the alleged infringement of Orange Book listed United States Patent Nos. 11,103,483 and 9,572,887, or the Asserted Patents, with respect to Hospira’s 505(b)(2) New Drug Application, or NDA, No. 211530. Pursuant to the terms of the Agreement, the Company will grant Hospira a license to market Hospira’s product made under NDA 211530 in the United States beginning on January 17, 2028 (subject to U.S. Food and Drug Administration approval), or earlier under certain circumstances. Additionally, in accordance with the Agreement, the parties will terminate all ongoing litigation among the Company, Teva Pharmaceuticals International, GmbH and Cephalon, Inc. and Hospira regarding the Asserted Patents pending in the United States District Court for the District of Delaware. The Agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

 

On April 19, 2022, the Company issued a press release announcing the Settlement Agreement.

 

A copy of the full text of the press release referenced above is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Safe Harbor for Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” “opportunity,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events such as: statements regarding the resolution of patent litigation and all related settlement terms, including the date of market entry and the potential for earlier market entry under certain circumstances and submission of the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review; statements regarding the strength of the Company’s intellectual property rights for BENDEKA and BELRAPZO and the defense and enforcement of intellectual property rights; the timing, scope or likelihood and timing of regulatory filings and approvals from the FDA for the Company’s product candidates; and the ability of the Company’s executive team to execute on the Company’s strategy and build stockholder value. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the COVID-19 pandemic and geopolitical events such as the conflict in Ukraine, including disruption or impact in the sales of the Company's marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company's third party partners and disruption of the global economy, and the overall impact of the COVID-19 pandemic or other events on the Company's business, financial condition and results of operations; whether the Company will incur unforeseen expenses or liabilities or other market factors; whether the Company will successfully implement its development plan for its product candidates; delay in or failure to obtain regulatory approval of the Company's or its partners’ product candidates; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of its products or that may have an impact on any of the Company’s products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects of public health issues, including the COVID-19 pandemic and geopolitical events, on economic activity and the performance of the financial markets generally; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the risks inherent in the early stages of drug development and in conducting clinical trials; and factors in addition to the foregoing that may impact the Company’s expectations, including among other things, any potential business development transactions, acquisitions, restructurings or legal settlements, in addition to any unanticipated factors, that may cause the Company’s actual results and outcomes to materially differ; and those risks and uncertainties identified in the “Risk Factors” section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 8, 2022, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

 

 

 

Item 9.01           Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release of the Company, dated April 19, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: April 19, 2022 EAGLE PHARMACEUTICALS, INC.
 
  By:  /s/ Scott Tarriff
    Scott Tarriff
    Chief Executive Officer

 

 

 

 

 EX-99.1 2 tm2212889d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

For Immediate Release

 

Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

 

WOODCLIFF LAKE, N.J. — April 19, 2022 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Hospira, Inc (“Hospira”). Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application (“NDA”) referencing BENDEKA®. The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances.

 

“We are pleased with the outcome of the settlement, as we continue to expand and vigorously defend the intellectual property around BENDEKA and our bendamustine franchise through patent enforcement and litigation,” stated Scott Tarriff, President and Chief Executive Officer.

 

Eagle previously asserted several Orange Book-listed patents against Slayback Pharma LLC, Apotex Inc. (“Apotex”) et al, Mylan Laboratories Limited (“Mylan”), and Fresenius Kabi USA, LLC (“Fresenius”), related to their respective abbreviated new drug applications (ANDA’s) referencing BENDEKA. On July 6, 2020, the District Court for the District of Delaware had held these asserted patents both valid and infringed. Apotex, Mylan, and Fresenius appealed this ruling. Prior to the appellate hearing, Eagle settled the litigation with Fresenius, which can market its products beginning in January 2029, or earlier based on certain circumstances. On August 13, 2021, the United States Court of Appeals for the Federal Circuit affirmed that the asserted patents were both valid and infringed. Apotex filed a petition for certiorari on December 14, 2021, which the Supreme Court denied on February 22, 2022. The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

 

As previously reported, the U.S. Patent and Trademark Office granted Eagle U.S. Patent No. 11,103,483, entitled “Formulations of Bendamustine,” which is listed in the Orange Book and expires in January 2031.

 

About Eagle Pharmaceuticals, Inc.

 

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin injection, PEMFEXY™, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” “opportunity,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events such as: statements regarding the resolution of patent litigation and all related settlement terms, including the date of market entry and the potential for earlier market entry under certain circumstances and submission of the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review; statements regarding the strength of the Company’s intellectual property rights for BENDEKA and BELRAPZO and the defense and enforcement of intellectual property rights; the timing, scope or likelihood and timing of regulatory filings and approvals from the FDA for the Company’s product candidates; and the ability of the Company’s executive team to execute on the Company’s strategy and build stockholder value. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the COVID-19 pandemic and geopolitical events such as the conflict in Ukraine, including disruption or impact in the sales of the Company's marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company's third party partners and disruption of the global economy, and the overall impact of the COVID-19 pandemic or other events on the Company's business, financial condition and results of operations; whether the Company will incur unforeseen expenses or liabilities or other market factors; whether the Company will successfully implement its development plan for its product candidates; delay in or failure to obtain regulatory approval of the Company's or its partners’ product candidates; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of its products or that may have an impact on any of the Company’s products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects of public health issues, including the COVID-19 pandemic and geopolitical events, on economic activity and the performance of the financial markets generally; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the risks inherent in the early stages of drug development and in conducting clinical trials; and factors in addition to the foregoing that may impact the Company’s expectations, including among other things, any potential business development transactions, acquisitions, restructurings or legal settlements, in addition to any unanticipated factors, that may cause the Company’s actual results and outcomes to materially differ; and those risks and uncertainties identified in the “Risk Factors” section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 8, 2022, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

 

 

 

Investor Relations for Eagle Pharmaceuticals, Inc.:

Lisa M. Wilson

In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

 

 

 

 GRAPHIC 3 tm2212889d1_ex99-1img001.jpg GRAPHIC begin 644 tm2212889d1_ex99-1img001.jpg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end EX-101.SCH 4 egrx-20220419.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 egrx-20220419_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 egrx-20220419_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Apr. 19, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 19, 2022
Entity File Number 001-36306
Entity Registrant Name Eagle Pharmaceuticals, Inc.
Entity Central Index Key 0000827871
Entity Tax Identification Number 20-8179278
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 50 Tice Boulevard
Entity Address, Address Line Two Suite 315
Entity Address, City or Town Woodcliff Lake
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07677
City Area Code 201
Local Phone Number 326-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock (par value $0.001 per share)
Trading Symbol EGRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2212889d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000827871 2022-04-19 2022-04-19 iso4217:USD shares iso4217:USD shares 0000827871 false 8-K 2022-04-19 Eagle Pharmaceuticals, Inc. DE 001-36306 20-8179278 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 201 326-5300 false false false false Common Stock (par value $0.001 per share) EGRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eagleus.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2212889d1_8k.htm egrx-20220419.xsd egrx-20220419_lab.xml egrx-20220419_pre.xml tm2212889d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2212889d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2212889d1_8k.htm" ] }, "labelLink": { "local": [ "egrx-20220419_lab.xml" ] }, "presentationLink": { "local": [ "egrx-20220419_pre.xml" ] }, "schema": { "local": [ "egrx-20220419.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "egrx", "nsuri": "http://eagleus.com/20220419", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2212889d1_8k.htm", "contextRef": "From2022-04-19to2022-04-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://eagleus.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2212889d1_8k.htm", "contextRef": "From2022-04-19to2022-04-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-047062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-047062-xbrl.zip M4$L#!!0 ( !@XDU2 V ]U.0, /(+ 1 96=R>"TR,#(R,#0Q.2YX MGT9?/A1&\U&R_W?)LWDX ,+_(CVRIZ@(0@4PRN M.I[-KTAOV*@).?#K01#Z=^?=:X?S+@4H+(:$YE[@$P(B(%J:GIT*DI MST.GVM*_31V#[#G*0_Z_2)F1WJHI&PJP_YAKU^I/)UG,AS\9D&(_.T1MDZZ0 M&O&Y85ST/.8/>U=$3FH!Q>YPR4MJ(Q5/(ETEB,D-K!9$R5LCB#**U3CCSGX=WQ./$U@CH5;%C+7TK M9*4#JU-?$-3?F&ZOUFJ12&17X9)-,DTI-^XZ5J[,[*=^N:*4K+P@]NO_ MCN:H_O.P;B!OMT;;SS7-\@]02P,$% @ &#B35-^\/$'OV7?H&F_)*?J14,)QSOAWZ!M. M=W(+NTQ2PM&<;9]2DA.14.[X%/WU:#J+T'@\(-]OA,:,?[U;U/D^Y/E3=CJ9 MO+R\'%'VC%\8?\R.(K8=EN$RQ_DNJW/[N/]8_93AG]*$/I[*7VN<$22.%\U. M]UER-I+[K7;['JTS^*1.OC%$>0L)7?D'A7%/,U?GP1*62))&%7;'CBYMYM).9_(^ DE M&YR36.[H1.YH^C>YHS]6FZ_PFJ0C))6"#[!<)ZV\JJ"):[.WA"[(OOCL\_Q\*T(QW7H05RW'Z+O/-2.>VK\G[CO@ASOV1%NT\>=^1;D3^7VSG MIN4W'U[[<4WEQBOQJ661['/1@9%8F919=+3 Q1Z*CJ'*N\Z=1:U\4]F:,VZ6 M7?:,19X9B8XV['D2DT3D/9O^YR_RX[C\6!1=_/O;G(G1P/DZRSF.]12P4DPB)KJGIWRR#+_G;&O=;55R9DG\+5W7\>6A M$;L C+9DG&1LQR/RIIIINH6.4N5HFPJ%'%81.OZZ''U?:-"O2O7O3Y-#+HXJ M6PR%=EM"\Y7(U5**=K*KJK:94C7=3 NBHBV&]'I6$B0U'BKY7.P\E@8N4[RQ M%$%+=U7-5ENJGEN)052TS9%>T[4&29'/JOY"LH@G3W)XWU66ELQYQ5M,&O7? MT(2%@6D,IJ&A]=C(WY%-(KL::4.>\Q*YL:-) _2NNX%.VWJ_8!4' 'TCCPQWH506^::')M)'9BF)BA.+,9 /$HM*L4>J?C[3IS- M$YZ^]H)A*%VS 5C5\=!D01%B]P9"4LO]<[+BF&:);,QZ03&ESD]# +/&*8FF M"XH5P!Q\JE+K_=.R?"!I*N\98-K?L-C$KHF!#>O,F,J@J 'M@=P4$:@*"0N= MBV+D>YP($E%&))Q'FEJW++HX2EE*-"'P8H%S0>A$FM\P.)9M..2"4*$)"VLSX\A-HW')=)%N&T M]',IMF4=1;1H74,"VM5!,81!P0*Y X$I Q0W18AW:/Y),!^&3$/I!QC#JAV7 M6A8@++JW/E2DWALH\QWG+>=P[P-+G=W,[3%;W]<%=$' TF/.N-M;RENP>.R- M+FB>Y*_R>;SKW79-N*6 IL05'Y YQ86>'@0/@"F=@U*&I Z50F^UK^XJT%P^ M" D629>YIX/CEB=;S%^72=33;9A"MWA 1MM\Z*J &L M 814:K1,32$^46K$%%:./5&1(09$-\ JBU0C^4S[0@ M)N<&%1D@F8,WZL[C6!RLK/ISE5 R!8^!5>N6L Z[;:XLPH!H@MT!#%7*#^H# MDC'HAH8$SNP-Q9WY!V1*=6^L;AE68[3?R5/G2?I=K$71*R&K:"TE.'A8K/7!TT9@T20 MKY/N"EMY \0Z74U+=S?EV&+K,.6XD1@$"#9'YI3C\NI**?)1U9)53C#0,K23 MG56TQ51=SXVT,*K9-&34-Z>A"U M#IC2:[Z0H4+G\ZA1G_A22[V M/F?;[8Y6=X9LSR ".E4(W/XN3 M4YY@6\EL(E=0P 85$:8B"!Q 6SH+!R%22@\@W'(B822B,HH)AW*1(WYS?V_M M_;O$KL#H-ZP @95!@-)K3P=&!(RC1@0J0U 1XQ^=19;M"'\30)803QB!Y@&8 M#'V(2$$F>\$J WWSM2313O27K]/9>I7DJ>W$TY0XZY\ A M2$/L'DUG?UK_&:DH#PAMVS5)@)2RKRA4('185"Q9)$#C OG0B MKAFJI*C4^EHIJV784B0MW14$5ENJ^EN)052\S9'1"+3JVV/S?[&/'H0Q DQV ML,M<=P,VDWI7T-0$@4&',>-DI9(BI?4UV>'0A6WZ!P4;;X."3<^@8!/BH& S M=%"P\3HH4+LNERD1;=3-.DTV&%@TL5/M&HP.RSHC%FE0N,#^P+:C#D&'&!^K M;1;+KLE7"?!MX>%2?+"4%- Y6V^SRV:]X*9-% 0G7]X'GT8' TS:2!5AJDU%NO PS*< M/BZ[EP]Q_$+2]"?*7NB2X(Q1$I?76VQWE[KU;I^ZZ;'=?O &$ >!U!"'P.,W M,FC\**.0"JNNEGFCZ1M+=S3'O)C#SFTM%*!S2P]@LTV-)@J(%KLS@)):C$JU MOTGAY>H5]<"K?&<26$A([GB*>*=I;::X51L0-YT&H7GCU9HCA_%R&>5Q.F=. MY+LNDF?R!>>X\@>6&9*[GL#995J?N6G3!H11IT%PKF8=(Y>KP8HKK\O6\+D8 M?FU8Q]/GFLK]XC6&17/]FEH2$"(V7QVKV'"DM-YX6&YQFG[>90DE&=PI:2JW M/%@MMGEH20+BP>8+X*&0(J7UQL/%EO"-Z.Y^Y.PE?ZC6D 7+!ZC=\M%IN A$MKD3I&!S2K<6/H0H(&,F<0DY)( M7H^Y9CE:,?0U(RA_(.BB>JU><^7Z,A^?;TF)(CGAHARMTQAS&T9=8N=O3 $- M&^]-,91!P-1K#WZ'2AV!5(@'1D"\ZDZ ]Q1=%0\XJE/GT0 M1 TTJ7-5A+5/O(M )"-]KZK47) ?'O:U1(Y'RQ:#VF"YH0B"$] 6-%1NOM_ MWWI^NW6:1)9-16H3-2@T(-;>XA>@\) %:N3QH=%[^;[@ M)Q]&ERO,L>AQ^8#%0;S9Y9GL484Y^(IY9Y#C6Q$#"J#=D.B(" B_ 3:AFQ-% M)"I"/Z RB/9ZW98?5"4G\^?6.W!,NYS2LR#[_+';VV''F,2#6]5G=X.+H M)WF]@4& ^%:WT"E@AIH9H+5\SJS* OTJ,T%%+K;WM#"TR,#(R,#0Q M.5]P&ULS9Q-<]LV$(;OG>E_8-6S+$M.VMJQF[$5*Z.)$[N6D[2]9"!R M)6$, BI 6M*_+T"*BCX(<'W)V@=;)A? OL]"()< >/YVF8KH";3A2EZTND?' MK0ADK!(NIQ>MSZ/VY:@_'+8BDS&9,*$D7+2D:KW]\^>?(OMS_DN['0TXB.0L M>J?B]E!.U)OH$TOA+'H/$C3+E'X3?6$B=T?4@ O045^E.9^C9F!R/*2YFQI^$7+M;MN=G%RI/2TTSL^[G;^_G@SBF>0 MLC:7CEL,K:J4JZ6N7/?T]+13G*U,#RR78RVJ-DXZE3N;FNU9'K#?\L3P,U.X M=Z-BEA5A;VPF\EJX_]J56=L=:G=[[9/NT=(DK0I^05 K ?NJI_W3'*5G/;+PUWW:H5 M=7::G6LP(+-"Z8T]L%,$EIGM39!4%;GVD8YE/'.VZZ[2C=JN7^6I;"!7O-"XQ77XL,-A_OQ6-78Y- MIEF<5;4)-@91M/'-VNR9='Z09Q61!UMKO6.[%OM^;1T@EHR[RJB^EX M)V*'W7-MT9DS;2MJQS,N-L&>:)7Z"*UI*(^CV[!L$S^.Z*7U(7%^# 2;UB/= M,T$R[5) K55#2?4=F%CSN6/3 '?'$LFX1\JX1AL!ZNI[= ]3[GQV[K@+,+B# MX3'"4P0)_X1RU BJ)8S"I90Y$_4P#T*"9D_:"8-=XPPT ^MD=1_([TA\6@DQ#Z:@1 NR6,2U=OK[)'H M?Z=$[]?Y0N!?/[GKOKW82X!]S$3)1>#>PQ$T9>8X[%3I*;-LHD1_\/ M,(T&OV6,Q4Z2KC9()(#>S[7><2@XPOBML=A)$M4FD031]:83F3)*<^461\JR<3,G.3(2'&^Y98SB0Y:4@<&>N^U:29&,H$EA]@ M%8)]8(JE39*+!N61X;[3/&5Z->)Q\P!R:(L%3I*!A@62$7]@RV%BE?$)+Z<6 MF\%[BV#YDZ2?*+ED81C*6.FYVGKY_6ZN^BH)#O$-!;$A(WCT)/EJH\P7A/[D>>A/\.A) M,PS+J$:< RLL;Y+4T">*@.\G]:"9VT$X6J5C)?Q;56H-L91)$L& - +0 M.[[4(]XSP<(ER0!KY1".#]?+>,;D%/PK(^HML9!),L*0.-*Q>(H:BZ?/'(M) M,D.?*$*^Y?IT^^VZ'0L^9?X=;L$"Z'T_E-0#4BGV%A;;D-Q^0E&X-N&0RMJG79L^=)Y-O+H4- LT>3Z1HLBF"KR#$ M!ZD6<@3,* E)F0Z$9@F\1;"1()R3;)!+%H8O2N26E"X6H&K/=\%CBL5..!?I MD4>WWK-<5+VY'I4O&@E1]Y7 PB>A&/A*8&- M.$$9%DNZAE_W[<5HJL)S\7N&6.*$2W!KI9&!'J5,B*O<< DF.,[L&6)!$ZZU MK95&!OHZ!3VU@]Q[K1;9;+W_- 3<4P +GG!%;5 J70"6W_>]EWOS@O1KK-%O M5"!$[Q5)^KOU]H'@Y7;'#LN<,(&M$T:WCRL?"QX/A&+!^_8=,RQC MPFRU1A89XBLF'W4^S^+5G58Q@)N&,9MO'B)I0E: #0MA'OLL%'2/%E2:N@U. M*GX@07*UNH<):+<$X@&6 MV95M[#%\LX0HCHT1Z9N1T!AJ0G7>.=!U8P^X-_&69]PO][99>^1_4$L#!!0 M ( !@XDU1RQ.6;=AL &V! 2 =&TR,C$R.#@Y9#%?.&LN:'1M[3UK M5]NZLM]9B_^@FWWW.;!.7DX(!&@Y*PVAI:5 $UK8?&$IMI*H^(5E0])??VT% M*!R4FH5_[ZVNO!F%, [&NN)M812&_DZEZ*D+HF2QZRN7N]&#[>38;V YMGAN*5>))Z90XT MW+6F#Z0';U;4S!LU8^L^/-2(Y('QHK$&X@PK9!?OND?3 MX6'^^.G02AA05PR\P*$A\! A-4K56JFVF0)2$LS, (+/Y:%W^R"<9JENQ'#F MF)-=*=[N4Y%0W&(SY([GA!OP1,VXV8B'!FRP$/!F!>[& R-1&E+J)X,'5/3E M0'U#PBU5C136<"?P;"9RGY%W1/RT&9[;RKJ)]QU6$@)@BBQFXC? MOBVT/3=D;E@ZF_C %-]>EL(V3BL*+6LX',5#?;-_Y1*Y( SV]HA/1;NDF/J ML!TRML:[Y'!?_G)5K;6NOO;^K.V_;[5.X0>NA)1*CWVZ;ESA2J]2*[R*5_@$ M,!NMY*F?>;S1O&(@;X ^_-=Q@8"3-E FH/:A:['Q)S:YJL*?9FVKN?64U36V M4W!;#G,M^#\\L.GP:D!MP9X :O,=D'G_RKC2ID+!A$M/@5&[ZHUHP,15[4I: M1@5$R&M/@;./N)QJ6/4YE!8"[WO6A(AP8K.WA0%(WPXQJGY(SK@#0X[9'>EZ M#G6+ZD(1$ CX0,JYQ6_CYRPN?)M.=HCKN4S>Y.,=%%@6H";(3]RRF"OU C_" MP./( 5BF$OEQV$5+# M85(J=C0Q"+?N)49LU>+'F.1#!M0\_97DV^_!TNDKN M?'HV'^CK6?-80!01A/LT9'O3)<20IO?F'@-6+G@HOC.+5@:!^*(F:9;.DKVTVDPBV,>U-2D^\SU'.X^-.W#=)F=-P]P?#]#A3F":@U- MZ:,R#['5?%.!Y^$G_DU[@&YDL](I'4I'E3;"#@V&W"V%G@\FO.:#G]!7^EX8 M>LX.J>.U.VZ%([3QU3\+FUA$IV#7YV!3L$_4]U"L275)@.TUZJ^9"7 MVB6H@25J\R$ -<%ZL" ABEQG-8=*5<3_37_OZ_'A66>?],Y:9YW>FTI_[W[_#D^%[T'O3FST/OG(H1 MI)RA!U#WR^WRZDJMVMC8_FTH_5ZI.3CI?B9OA$]=:2,Q--NN'LB(LU3:]\P( MPP0,]:_,)#B>ALD_//K>N/[4KO]H] '<<^.D]'R%O6;ITVQ0\J:"F.Z]5EZ] ML.2"6G4[QV>DVSD]Z9[]38EP&@4BHFY(0@_ F5A 6%TQZL0+B-%8L]9_IVGQ M!B0<,40K"GC(F0#C-S9'U 7'T3)# O>-[?K&WY%S&(CB^KO,]X*0K.G/JRN, M0I3!1$C8+< C@;S/K/4= @3%_V9LT_Z,;3J5P6Q'A;KY1JI^<;SOG[IU%A@_ M;:32:94%,SGPW,BBDPG@S]P\(Y9!K+#7\@-N _N+!,'>:]A^GP#' O+[@H=9 M=M)>RX@[R),7 M@#V49?)>"':DK0K";<]:(/V^USKIOV]6ZB)5-QY/52-#U0-N,T"ASX)\$EJ<\6^-.\?^,5B: 9G. MB24DHU3?K%O[S80UED:$)9Z$!,&Y#N$A,+B M,F %0YPLX-%\SN/M6MMS'"YP1Y6@B!%%N742&\WG03_L]DC'\6UO @O(LH@< M>^7,-*^* ^#-4A9I?3G$7@I-.(N\S(-W;FS5^3F_/]IK?)EV;L3D7=>9+-;&E@+[%UQKE1C M/+"RVH(P86B<@%I??KZKO^#*:H6]7L0AT:L;C7LL.&1Z@=HT?LA5:=AM^/4D M.//NW/S51;;#S,./G4'#6O;JIE,7]LX]SS)M/AB0(WJ]*+IY),NDRS@)3B'* M MNU(+AK-(Z_;V_V#.-D8]GKFIF_L'?\\=GAB;(W4R.P0%^?8E=G0&YL_VS0 MHY=]ZD%P:U]R?W%$?=/^=G%4EJ4^,2 ]I[CJ^S*7.HT@HSMH M?7NW#*QGYRSLU6N;I4:]6GUM!:#G2VAFFS.+"99J"GOM$3.O9>F;^G[@@47! MZF[?&Y,^L[T[PE5=_, +'-(L?2(#;J- <@'2&3+78A9(KD<$=R([I"[S(F%/ MB(#@70PF\E']A->':65,+TT7WID6M$@$D )"W4E\;P#QI7>'#V+U@F.:)':6 M1HFEDS8GW2D-J,/MR0XYAU6@%HO"G&-K:#4X#W@(U,24,')UFB;R=8&UHB]# M_LGZV/_Y0.(QC4:Y*"FZ-7<7*HK\H6BK :RNF!D0Q$_M N'F/-FH-33_LSLP MU>[YI-1N]?Y^5W=QXC'/#Y/D8WITZLKCGY^7C",#5HR M:BG9R.S()9*Q42VKD7];X3@-&.HIMM_)/7BTR\')8+#(GU9O;.,[[?H?O_]\ M7/P8(5F,UU.$!:"4S!28ARV*L6&5:FO]]<>)CAK[MQ,>(U]X#H6(6/"@"$5C MUSM[=[?/Q[]2@N:0>V$YJK/2QIKY.#G28U]"CI:=JV#HMS@$#?APA)MX^3%I MND-"!7 L8%:&=KJW@QA2!W5 !_1:7OQV#VE>0S4T!I\7^.>GWH7YW%JC&[.C M4=Y 'L57U4:KOCA3>Y]N+!E__G0='O+,,SQ(@OQCU!P1TZ9"J%3HGI+\$K"N M_3E](!:]3*?G_9_(''2>[;/(13V7NA=-2U.+#:D8"CN M1ARN3*W)+"&GA;-["D_/4Z&7W-):Y'FU*9T8M;Y4M04EF\F1=[[)FD%K&?7^ MV3D+>^A?@0>]T#.OR9I/ W)+[8B1_ZV6JU6#^'BR KO4U^_WL<^6O$=Q8$E2 M_BNY'1>OM:U0IB*?U71R\?G2$>-A]WH)K,Y,6-CKO.]>_)>%2U'8. A/)P*>V<0<1U38=$;K=B?:7#-0G)TU'Z$#"RE M+O^R!;>\6N:A:V$LSTA_0DQ9UX1'KL&[,-G&,5-RY(( DR$30*C#U95AX-V% M$.9XCH]U2"J(Q0;<5?UUJE!5;9"Y/N%4=W ]20APL5N[LF95;:QC)XG*)VK] M4BT'1,R[U954J_$L,,PQ\/GU\NLM@\I_&_.)K^P&[&A2DQE*_U3VFMT2C$&_ MEY#;"O""'M/FCWYX0=O5NQ=-7._!ZW$YZZ_AR:_0RD%:SV:8CYMN!.P&ZY@.= T:EK8A62FO+D/@[&=T-8-+ @TY6;$-:B/+>^1I,\-UT@ M*#].MF-Q6"[?YYC[U(-]]9QM*778[PD'^U(']W(/]J4._BWG8-_/%]&66(_+ M(3EBN@OC;R*L/P%8=29>!D#S%%QX^O'!DY>;,N[).^>8%HCXQ.?<] &CUZ4^ M ZT!''V)?@\XNLZUGS1:JXW?=X65I,KVG)]CT3(!Y,7 M*-6^A,,UYHV[O-0'V0%S&[D6EJJ\8 <3;3S0 @GY8<@!9(E)^[9[Z,5;Y:KMV#](E+Y'$C-6-\YJB(ODIZE\$ G^X!:_%4'D^ZYSO-_YU (X M6QN[9"V@/K?L"6 ZB-!)]\''4P=5TV5D-+$"SQP![< OKY?)V0@"^M0*\+B[ M?8M5:I_B:VZ(#8M4#0BD#Y2'!!-#CA0Z$!=8\B"-(W,EV7M @]!E@2!G[);. M4ID<(B5="9+:1?+>Z7^0,-K,'U';#: @2Z=MZET1" M/MYO%;&+7*VO9A@-R'1(^G@GS@W$<9)>CY3,I$E^QVT;4R]\3",",@F3,1=# M.T_S8@[)6&(<:C&].P-($86*0@NR-IPI2[P^A).N*_M17/*1NA$-)EK5MHIX MG+S6)&LBZG\'ZN#T7\N],CGP((Y$^BIB6 XH#,:D4I9DV\PMM=!A\L",'/6J,>!:R[*X$AI;!L RY@PLO*O8DT,PE$1,%9%@DK+X(@@I M1;"2H8W8+0..*78A>$\"*W6:\4\ MR!,#&(G5,$F.^- %/AJ/6EW99TCA6 D_HI$QV?(R[7LL_N_W+6F%Y+C#:JVN M4% Q[#(%N\4HJ")U78!HQAS/\P;_8=1J@:3YTWZT2.K=.(PO9,B#>:I^_Q%8 MBKX'SA0D=WT1"!XQ\H 'D0]) %G 'EBE(_"+4[D0;88=1Y?B4_)X&_!8] M2*H,>31U(%W, )UI;7.[441!IHXLLQ11+B'$DV55,04 -EN4$U;%^(B$5=C' MG/X8CF@HKV$Y!Q8=0C ';HD,J DI!#D'IRBD"OBC +0,XKO(' $>JRL8"-2J MNQ V<&R ![4HRDO&+M&W-%5F+Z/_G+OF1?;<0(=.9B\%S &"QU<3)'PO5-YH M=CR8"' J;/8R&_NRB#5[O<\@=+B=&^[;U)V]YD*^*6INN0Q\(#;G)=>EL^4.MW%R6 5:0-DX@RR,VX'1M.GWJDWF M1'/*>^G8148:5+L[*Y)^-)4*&^8+)=1B:JRL"^H 1%%!O8,BD9"=;.5-Z]8.(=;5F,VFA"A.-A9[(^P,#3P?5@D.#_<%I<6+ M0.7<(\@8! ,.HWN;7 MH%2C. U0]_4K&2(;7\@&W%!][HKR<5( J :>HSKH(3T99'/QN6S&A&R%W!Q+10K($A4%]$C%$%B54^_:O' QRV.)Y0B6P( M&X('JR4N0^:B[$'"WV<33R]?8_]/&?>'@6<7E=@H("5/ J MWNH*3B+U1?46 TS-"$_@;H$T73+YEED;OLX27Z0!OP(KOJLMAOZDJ$\B+':O M4LM2-JV'Y)+$@ @:[F6(\9"!VY'3 2[H_1)^GWP[W"\9VY @K8[W-2D\GP/ M30]ZRZSEDT]ACF3+% N8\_4Z Q8VOQ87 21KVQ9H*>,DS5!;29FQ.V?<5$$ M=T"4L$IS!M35<,3TN#RU\$WA0&99JQ)2)DW0#8ELB.R 9RTPDA,D24J'M/&0 M0A-A#! %\O"3-&6^;^,&$4I;9M[B['PH]R-&[7!D HU75\1$ ']PRNFB]5)1 M][-'4J;KA;@IL&3:/9F6@1"5-.W40T/;ZR,?@.J>,RDFJ@MI ,HS,$$1>"%+ M$])I5F8U%Y#I1P(X*& 1TXTJF$V5$>1\L?##'--5[<9[W\"#F:(+"D.$=0JL M] O&7-0*-)E"&3QE=CA+\54['V2,%TQAS]5S4!+!!0E,F292MW2[+=;6+%BB M[?G2&&-D(VTBWLBS@5)(D%F8!%!NHY\'8?+ZRNA,!2>VM_-L5-#172L6:C.8 M.UW>@DP,(M+KT51 FLMFX@"9P7^PA8N0VY@:Q#Q^JBX(O!IQ7ZCJCP2DT54. MB=["XF-'(.-AB).36'XJI^H%GU,5518Y-H(:F!>%@+B,/%+!"W=O/?M6J9LT MV*GE"%5-I%ANFY 1O46_&EL-*7^+W)/<.)4@=E-45/NQ/%OO0O^(2U.R-D3= M<5%*I&&7C%:AIBI%8H^O=!^*WHF_G;$=X)6IJ06YF"%+!984:Q5R23L?K<2J M&4"IUUS<-@W-YBS/@/A1'_#3!@A$'LLI;=2+2-X$)8J5_U@$)"8LD+X( M"1G7*1+[H 056)#XU=ULY)6*C?*#C'\^$(;I:";^E)9%CC1%-K.0J_?\2?^K MF.MGBI J#N% 5'/D0C .D8EJ#N ZC)T/AU. E5^72P0*86!,52ZAHUI%!:V% M*DSA+E90W,3A87"-KR6G0^7W+*SRINV4+,*X4B) ?)"),^Y,16O:,,J"KJ[P MQK$U&EE9I$5#K/5(ZT]^4(<9(IV3/E76];21PFBS*)5O2IU8I#/XRZ8(:BIP M$)B8-Q$7L6R#]0^#2.N+,OX0J-NI5$$49Y>$6ZR)J>447HXK'7[7,X[L#BN>90R_N@+L00I,6VG &9MR*R7"5%=;9Q6(B/D@.!WT8JJP^#[1=:J8,5S< MTQ3S0 %MKK]3%\E65Q;53X7/Z#5TFO W?52)YUEBY(OIYM-I.1FQ0 M:QST M28XL:; MC.Z_!"]_^S$[/#>P\#C0PD-U,^:A/VL>XOF;?S[F-,%SI""S)WCLE1\\/!8? MQ,I];=(3SUD\D@Q;VR].AGTFS(#+,.>%_)KV4N'W>"DP73)[Z9ZTG\SB76ZR7, MJ=Q;[^K6@VR07I1QCY77R5">)>:+2=#25FI4-Y[TALN7Y/[RHG(LWLB +>X> M C+2I&V1JO>=KF'69%DZ1]))VZ'\ID&"7S5(+/TV]O5ROE58WNFD7]%$BN40 M";C+K-\4,M?_&S*_3,C\HJ=H4N]%[!V^/VZ=?>T^\"5!2YKO]>4!67R3[OVR M/,HTVWZJ4W85(C_RZSU47M_-GCFR(EN7LRQ5OU!?=('S]"&Q!Z+AUJ%Z!W^? MC:@]B!L095U #\":8X1520F.1N'("\!F6LMLW^GAVV6T>]N _VN%V>BRP>O^P$N?J34Z.\UT^_+-'3;VN^/[YX.D0 ^&ZR M\X0,)?=;X)XTYP9.6A$5TC,!)CFC =P=_#IR+H>$RX+R(D3@(<6]K^6LXG7QWS#_ZO[U\UAL'5@?;1&SF32_]<'T^Z_MV\[E^<'EY?!QN7A MA<][7\*S0_-X;#OL;KQUXX>=P6'SK\GG4.P/>P>#X-WGH^/F^2?SLF9L_ZNR MU;);G_:'7;?6H->'7YQH^_V&9;?YL5]]9-^?B_?%-[=/^1>7$ZVW?^A_MR+\XKW]K6=ZE:-UXMR>5ZV/Q[&<\YOOE^<\=[YV=' .:\?_W"=F[^^&?S#4WY[,3P^VG5_XNVN?WWTZNKT@QC=?K@8_KPS,6EQ M*'I[62%N=:)R<:GNQ8U)9!JX!X$8*:LG.UB(I=?5ND3:J4X/Q=[.\;?I.,_Z M1[O7:Y]\[M9]46^&3_?ZHE /14?&>HI'5D]GQ<[QT:OCX<-,CW7A3CLXZ/:. M=E\=?]U3OZIFL9J08N=O?Q&CFY.?=XID?[^W__+E0=3[MWHX..CT=#+=V^MU M_\BF.V)PF;'B/$E4I&6AQ(V*E( M7I\,W@:/3N^OA;JZ80GWX4S\8JC612YH5.E9@M(FO"66RLCM3W MHDP+'8O7,BVE73BM>S\%8G]O_^57S(G* E\\/-Y?79V>7)R?G8F+P9MA("Z[ MK[OBVV]>(AOZ8I!9'7L=#UC'_?K=5D<$[N/S-.RV6\\N91[)/P_%\)>;W[\7 MSVCE_EZ?%_+/O;Y 9!8S)?RK$Y-D,EWXE]_#1Y%<")FFIDQ#\ME,%D(78B9S M8=GED9 B7SI=5DX739\OI8)0_BC_JCJJZ_692>R8Y\IRB-P;<65E.E7BE3%W MG5CG]#A#_*1%CL.D3O.BCBR[C"R-URD\$-ER*F26Q;!.H4U:&^'R=% =W6Y9 M-5%6I:%.IW5,(I+6PI*BJRMN8:VM"F?6S!&@N3-2)1-9B@S,Z$*2P?UWJF ! ML2(JPT*,%0(BQ>'MUM:P#LA+2MI8*RO&@(Y(0),0-H+^(M0V+).\D/!0WGVZ MB((-G>G?*R&M$AFC8.0"A4QDRB(T"?Z<\%^71@X0$>)>B1 'Z[14[1;LJ!X0 MJ8@5_#O74V--F<<+$<&3:<3K-1(VCE58E#(F4V>P%V(9'^(#[V5>;DI8M0DX M$X1<.-.YPC[X?#KS$2=4.C$V](Y/HW8KUH6>H!Y+_0B::CJH7\2;4N<&XZ@_55JLM8KKA*Q>LR]KG^(Z?Z7L"A>PKK M60UD.$%L%F+B0;I^C PYA7SWE$8$F#,5<\PC8FNO5" Y-L6LW9JCC+EDT>G$ M0@P5=;W=O5795&)I*>BC9,R8KP'V98Q%7<2Q)F'8*/Q)3&:" )(V#3R(N]1U M:;A,$<\#ZB,"<3_3X4R$<.DF*N9+6(3,J_4>ECKX.Z (4[=;@W**_/;(^IS- MW7/F?I=R!(TH$!,=G*I.VX"/,!+6.X#943QKU!GD3\JS*#/DW M6.IT[2H#ZT-M['KQXB8@D5+!D M;%+&'E(0D*\:1:JN-RX X#(/N0A^$JX!QBPD70 F-AB# M&WR2\#[MAJJJH/"4%),R1C@10T&,,&"L:(7T8Q[NN!'AI;1P,M>R"-4V-IGC M12%0F18$."LM)Q)DAZ"%/8X]$F5#2F XG\ D5Q7+Y@Q'DA:^Q/E-'=:F9BZY MSE'#BI)545K(4<8%!5BB).$RM$ \)41\&3AR>@?HT_2SKWX(RSDA<-UT4$5L MR*;_(NTKR-=I&)= D+G,#?(.&)+B&0$/42QQ/7Q[-OS] [9Y\7*_'XB;#X/+ MJ]/A[^M,'1#W2&L9H/Q>W RN_W6U^>;V9CAXRUA?L<>N":9-#2Q MF2X<>[L<[2:J E!P1>AU=YG3&HU2B)Q2*\)$JYB^2ASD8ZXQ-24E^#?82R< M(*.(5$:#"S!%(9F["FIEQF%!I!D\6(;6X", 0Z%!H44$MZ+Z.=X)0P^BB&L( M]M1$5Q-?>RGNYE+'IS 9/MG/BFKO#LIU89)# M\2,] ]&$,^IGKV+BKCT5X,$AYUQDK> @R9BQS M4Z0?MTA$8O[=(QN&V27+.&,\46_RI RL-NII[2$ZQUK%7JM&8C(6N)K=;GEL1^D1"&>YV*C8M;BAV M$C%P_4#OX. '[I,EK!411>'6EO #)*]>CZ8!&'&V)D]>6YE IMUJ_)V1GY M M-86 BM1U$=I1K<%.[Y$?.1^5S2QTSD$4J5+E%8H8@KIZ:,M[X-)&+]4>@P##Y^M,:9S=>6.*D:OTQ%I:C:J/0HR1N?\RZ3]:?3$O4!F+7^W&1$.TMT*8M-@13H($)IN8C9 M.IKB&*=##ZZB1"#)B<0X*#IX1,;T?K+8B,ZE][E'J&I+5>&YK@5B7!8N6"@P M8M^$%R9H?HSJBHUI3V<& T6SQG4T#FDA,$6>'G-LL>E*TCX[CN[QL-4*%L@O1V&I+0 MM!\5;-K)-ZCXSB[JKF99OB?+9A1IW/R6J_GVOK1JK*IF:6/PU>C)?,O]^=U6 MN[72;@G?;;&DKH/KBZ-=LO]6:SI)"JO2*;B*EZPQ'F;6L'W$QJ-.US9[%N;Z MWHIYU6+RL(YF%M2?-$9K..UC._=Y,:*>)PYYB)O-9%C[ L!'[&3JB=] MA9(XR;1;[A$SL6TK8'F])"V/-+6P1/>Q 3 DHK$3+9VJE&(/WG &="%P,MJVA+N<8XP^-Y# M%W>T/.M!HQ'S2,.2*_Y@?!;CA>O%/U9A.FC%6^%FXPOT.>1D<5<"99OU%.QG.<0$9S:C*$@@]" MYX^JF10%N0-+(V#D@INZ9@HY\-C6<>9EEB$PPIGDMJUQ;K!Q'OPR4S(N9MPV MY8L<[J$C:Z4K32GUER.0%74)\;6E:1N! _T_8M,YM;&/7S6-S9C\ *N;9!'4 MJ6MX>!U7]GW4H[7EO"=7$Y>$&9U-< MM]HWUZX.,"&V.JS)_#),JNS:H&U+ M9K8!/&"%Y9@F-PY_!+A3J=8W:+<^&],#,F\MDJ0KHBH$6!)EN121(;T#EO#@ M C5?5M7^*N_BB9^G1MLYQG>?8&&>S%1_:\:B)IN2F^M;!ZJ^SK=K\TB68ZQA MU'"6NDF8&U%JSV(WV?#&QJPC+$2T6+I6PI-:9X6^%Y3JLDYG=%]6ESNBU@LJ MXE.:J$$+OG)KXI2[6.&(0/B0%]?*F2-K'A?I4^D'916U)I"=&N=_GT8^?;93 M.NH07< '-%6O@D@Q21S8"3;VF=*J17Y">;Y#*LJF7X9ZGS*K0!_H4M M?;HX[ =-CQN- H=OK1'?C].99=IHORO=@Z5^CIEM4V^-K;EKW0U]-\-]D*8DV@W?Q? % M%]++7Z;L==[4_'U![3=WN]0*-6_/GO>JVS-W\5;C6V/00NH,'T!EZ!:ET6(] M:X@]&I[4%]1X]9:&].Z$E^YW=1H#9(J'=@NL/.?!9"&J3F1Y^/"D2[]'%3&' M016%=\@"=,EL' ^/D9'44);4YWIP=CPDWZ3 36V9M],H*O!0Z^LX MM\J%O(/Y4V(0<57XL$F9\7'KK0Y?1TX(_"I>QL%M0B).A$(K_3:_4P\ZI\O; MPK,(KT:[M56/ISQR_)SI]_[_I]__.]/O\W2N:,+J?D>2N12AV:L=_;[[SX8;^S_]/! M\R]YCWLHCMX=Q_=LG7_JE"[. * +NBT[VGWW]6XI'OT=],\!@N=]<>6:\4-Q M(8& 3P87/IVDC_^Z_2[]-K_[]7[ZKP#^ U!+ 0(4 Q0 ( !@XDU2 V ]U M.0, /(+ 1 " 0 !E9W)X+3(P,C(P-#$Y+GAS9%!+ M 0(4 Q0 ( !@XDU3?O#W'_PH &R' 5 " 6@# !E M9W)X+3(P,C(P-#$Y7VQA8BYX;6Q02P$"% ,4 " 8.)-4^@#K.%,' "_ M6 %0 @ &:#@ 96=R>"TR,#(R,#0Q.5]P&UL4$L! M A0#% @ &#B35'+$Y9MV&P ;8$ !( ( !(!8 '1M M,C(Q,C@X.60Q7SAK+FAT;5!+ 0(4 Q0 ( !@XDU0=D[3D_ X PP 6 M " <8Q !T;3(R,3(X.#ED,5]E>#DY+3$N:'1M4$L%!@ 0 % 4 20$ /9 $! end